Catalog No.
DHE01901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-lambda
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
CD27 ligand, CD70, TNFSF7, CD27LG, CD27L, CD70 antigen, Tumor necrosis factor ligand superfamily member 7, CD27-L
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P32970
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ARGX-110, CAS: 1399546-01-0
Clone ID
Cusatuzumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents., PMID:32601337
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia., PMID:33630233
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial., PMID:34251873
An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma., PMID:34405542
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma., PMID:34726773
Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment., PMID:36394119
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy., PMID:36779592
[Management of AML in the elderly]., PMID:36870810
METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer., PMID:37648786
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study., PMID:37914483
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial, PMID: 34251873
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia, PMID: 33630233
An open-label, non-randomized, Phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma, PMID: 34405542
The CD70 Antibody Cusatuzumab Shows Promise in Acute Myeloid Leukemia, PMID: 34383699
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents, PMID: 32601337
For research use only. Not for human or drug use.
